Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy

Hypertension

Volumn 61, Issue 6, 2013, Pages 1184-1192

  Hua, Yinan ^a   Xu, Xihui ^a   Shi, Guo Ping ^b   Chicco, Adam J ^c   Ren, Jun ^a   Nair, Sreejayan ^a  

^a UNIVERSITY OF WYOMING COLLEGE OF HEALTH SCIENCES   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

cardiac hypertrophy; cathepsin K; contractile function; mammalian target of rapamycin

Indexed keywords

CALCIUM ION; CATHEPSIN B; CATHEPSIN K; CATHEPSIN L; CATHEPSIN S; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHENYLEPHRINE;

ABDOMINAL AORTA; ANIMAL CELL; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE; CALCIUM CELL LEVEL; CELL SIZE; CLEARANCE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE SILENCING; HEART FUNCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HEART VOLUME; HEART WEIGHT; HUMAN; HUMAN TISSUE; INTRACELLULAR SIGNALING; MOUSE; MYOBLAST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; UPREGULATION; WILD TYPE;

CARDIAC HYPERTROPHY; CATHEPSIN K; CONTRACTILE FUNCTION; MAMMALIAN TARGET OF RAPAMYCIN;

ADULT; ANIMALS; BLOTTING, WESTERN; CALCIUM; CARDIOMEGALY; CATHEPSIN K; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION REGULATION; HEART VENTRICLES; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; VENTRICULAR PRESSURE; VENTRICULAR REMODELING; YOUNG ADULT;

EID: 84878922289     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.00947     Document Type: Article

References (25)

1. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006; 7: 589-600. (Pubitemid 44325350)
2. Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest. 2007; 117: 568-575. (Pubitemid 46348511)
3. Sam F, Siwik DA. Digesting the remodeled heart: role of lysosomal cysteine proteases in heart failure. Hypertension. 2006; 48: 830-831. (Pubitemid 44610992)
4. Qin Y, Shi GP. Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases. Pharmacol Ther. 2011; 131: 338-350.
5. Cheng XW, Obata K, Kuzuya M, et al. Elastolytic cathepsin induction/activation system exists in myocardium and is upregulated in hypertensive heart failure. Hypertension. 2006; 48: 979-987. (Pubitemid 44611013)
6. Cheng XW, Murohara T, Kuzuya M, Izawa H, Sasaki T, Obata K, Nagata K, Nishizawa T, Kobayashi M, Yamada T, Kim W, Sato K, Shi GP, Okumura K, Yokota M. Superoxide-dependent cathepsin activation is associated with hypertensive myocardial remodeling and represents a target for angiotensin II type 1 receptor blocker treatment. Am J Pathol. 2008; 173: 358-369.
7. Cheng XW, Kuzuya M, Sasaki T, Inoue A, Hu L, Song H, Huang Z, Li P, Takeshita K, Hirashiki A, Sato K, Shi GP, Okumura K, Murohara T. Inhibition of mineralocorticoid receptor is a renoprotective effect of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor pitavastatin. J Hypertens. 2011; 29: 542-552.
8. Garnero P, Borel O, Byrjalsen I, Ferreras M, Drake FH, McQueney MS, Foged NT, Delmas PD, Delaissé JM. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J Biol Chem. 1998; 273: 32347-32352. (Pubitemid 29177183)
9. Yang M, Sun J, Zhang T, Liu J, Zhang J, Shi MA, Darakhshan F, Guerre-Millo M, Clement K, Gelb BD, Dolgnov G, Shi GP. Deficiency and inhibition of cathepsin K reduce body weight gain and increase glucose metabolism in mice. Arterioscler Thromb Vasc Biol. 2008; 28: 2202-2208.
10. Hua Y, Zhang Y, Dolence J, Shi GP, Ren J, Nair S. Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction. Diabetes. 2013; 62: 498-509.
11. McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, Izumo S. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004; 109: 3050-3055. (Pubitemid 38808328)
12. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc Natl Acad Sci USA. 1998; 95: 13453-13458. (Pubitemid 28522993)
13. Wu JH, Hagaman J, Kim S, Reddick RL, Maeda N. Aortic constriction exacerbates atherosclerosis and induces cardiac dysfunction in mice lacking apolipoprotein E. Arterioscler Thromb Vasc Biol. 2002; 22: 469-475. (Pubitemid 34218756)
14. Dong F, Li Q, Sreejayan N, Nunn JM, Ren J. Metallothionein prevents high-fat diet induced cardiac contractile dysfunction: role of peroxisome proliferator activated receptor gamma coactivator 1alpha and mitochondrial biogenesis. Diabetes. 2007; 56: 2201-2212. (Pubitemid 47358226)
15. Li SY, Yang X, Ceylan-Isik AF, Du M, Sreejayan N, Ren J. Cardiac contractile dysfunction in Lep/Lep obesity is accompanied by NADPH oxidase activation, oxidative modification of sarco(endo)plasmic reticulum Ca2+-ATPase and myosin heavy chain isozyme switch. Diabetologia. 2006; 49: 1434-1446.
16. Hua Y, Zhang Y, Dolence J, Shi GP, Ren J, Nair S. Cathepsin K knockout mitigates high-fat diet-induced cardiac hypertrophy and contractile dysfunction. Diabetes. 2013; 62: 498-509.
17. Planavila A, Rodríguez-Calvo R, Jové M, Michalik L, Wahli W, Laguna JC, Vázquez-Carrera M. Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005; 65: 832-841. (Pubitemid 40249728)
18. Custodis F, Eberl M, Kilter H, Böhm M, Laufs U. Association of RhoGDIalpha with Rac1 GTPase mediates free radical production during myocardial hypertrophy. Cardiovasc Res. 2006; 71: 342-351.
19. Carrera AC. TOR signaling in mammals. J Cell Sci. 2004; 117(pt 20): 4615-4616. (Pubitemid 39433427)
20. Lange AW, Yutzey KE. NFATc1 expression in the developing heart valves is responsive to the RANKL pathway and is required for endocardial expression of cathepsin K. Dev Biol. 2006; 292: 407-417. (Pubitemid 46137883)
21. Cheng XW, Shi GP, Kuzuya M, Sasaki T, Okumura K, Murohara T. Role for cysteine protease cathepsins in heart disease: focus on biology and mechanisms with clinical implication. Circulation. 2012; 125: 1551-1562.
22. Reiser J, Adair B, Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest. 2010; 120: 3421-3431.
23. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol. 2007; 47: 443-467.
24. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, Kitsis RN, Molkentin JD. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 2000; 19: 6341-6350.
25. Asagiri M, Hirai T, Kunigami T, et al. Cathepsin K-dependent tolllike receptor 9 signaling revealed in experimental arthritis. Science. 2008; 319: 624-627. (Pubitemid 351197065)